Document:

EX-10.22

 Exhibit 10.22 

 
 

 
 April 3, 2018 
  

			
	Mr. Edward J. Borkowski	  	

 55 Dale Drive 
 Chatham, NJ 07928

 Dear Ed: 
 I am pleased to confirm our offer of employment
to you for the position of Executive Vice President of Corporate Affairs and Strategy on behalf of MiMedx Group, Inc. (“MiMedx” or “Company”), which employment is to commence on or about April 16, 2018. In this position, you
will initially report directly to Pete Petit, Chairman and Chief Executive Officer. 
 Your initial base salary will be $21,153.84 (gross before deductions)
per biweekly pay period, which is equivalent to the gross amount of $550,000 on an annualized basis. Your salary will be payable on a biweekly basis. Your future salary adjustments will be in accordance with Company policy and based upon individual
and Company performance. 
 You will be eligible to participate in the MiMedx 2018 Management Incentive Plan (“MIP”) with an annual target cash
bonus amount equal to sixty percent (60%) of the base salary paid to you in accordance with the terms of such program in effect from time-to-time. You will be eligible
to begin participating in the MIP effective April 1, 2018. 
 Your incentive will be calculated based on the achievement of MiMedx financial targets.
In the 2018 MIP, a specified portion of your above-referenced target bonus will be allocated to MiMedx revenue performance, and the remaining specified portion will be allocated to MiMedx Earnings Before Interest, Taxes, Depreciation and
Amortization (“EBITDA”) performance. Under separate cover, you will receive further confirmation of your participation in the 2018 MIP following the commencement of your employment. Your participation in the 2018 MIP will not be prorated
based on your participation date of April 1, 2018, but rather based on the full year of 2018. 
 The Company will make a recommendation to the
Compensation Committee that you be granted a Restricted Stock Award of 100,000 shares of MiMedx Common Stock. Such Restricted Stock Award will be subject to the terms of the applicable grant and the terms and conditions of the Company’s 2016
Equity and Cash Incentive Plan and the Restricted Stock Award Agreement. The “Restricted Periods” are the one year period beginning on the Grant Date and ending on the first anniversary of the Grant Date and the successive one-year periods ending on the second and third anniversaries of the Grant Date. Provided you remain an eligible participant in the Stock Incentive Plan, at the end of such Restricted Period, you shall become vested
in one-third of the shares of Restricted Stock, and shall own such shares free of all restrictions otherwise imposed by the Restricted Stock Award Agreement. The above recommendation will be made by the
Company at the next scheduled meeting of the Compensation Committee, which is scheduled to be held on April 25, 2018. 

  
 Innovations In
Regenerative Biomaterials 
 MiMedx Group, Inc. | 1775 West Oak Commons Ct NE | Marietta, GA 30062 | 770.651.9100 | Fax 770.590.3550
| www.mimedx.com 

 At the meeting of the Compensation Committee of the MiMedx Board of Directors coinciding with the
Company’s 2018 Annual Shareholder Meeting, which meeting will be held following the filing of the Company’s 2017 Annual Report on Form 10K and the filing of the Company’s Proxy, the Company will make a an additional
recommendation to the Compensation Committee that you be granted a Restricted Stock Award. The shares to be recommended will be equivalent to $750,000 in value based on the share price of the Company’s common stock as of the market close on the
date you commence employment with MiMedx. Such Restricted Stock Award will be subject to the terms of the applicable grant and the terms and conditions of the Company’s 2016 Equity and Cash Incentive Plan and the Restricted Stock Award
Agreement. The “Restricted Periods” are the one year period beginning on the Grant Date and ending on the first anniversary of the Grant Date and the successive one-year periods ending on the second
and third anniversaries of the Grant Date. Provided you remain an eligible participant in the Stock Incentive Plan, at the end of such Restricted Period, you shall become vested in one-third of the shares of
Restricted Stock, and shall own such shares free of all restrictions otherwise imposed by the Restricted Stock Award Agreement. 
 In the event that
specific events, as defined below, occur in advance of the MiMedx 2018 Annual Shareholder Meeting, and the above referenced recommended grant that was to be equivalent to $750,000 in value is not able to be made to the Compensation Committee, you
will be eligible to receive the equivalent value of the above referenced grant paid to you in the form of a lump sum payment in the amount of $750,000 (gross before deductions). The specific events that could occur prior to the MiMedx 2018 Annual
Shareholder Meeting which would cause the $750,000 cash payment to become eligible to be generated by the Company are limited to the following events: 1) the consummation of a Change in Control (as defined in the Company’s Change in Control
Severance and Restrictive Covenant Agreement referenced below); or 2) your termination of employment without Cause or Good Reason (Cause or Good Reason as defined below in the Non-CIC Severance Agreement).

 Based on the Company’s analysis of competitive data, the Company has established a target annual long-term incentive value for each position
eligible to participate in the Company’s stock incentive program. This target is expressed as a percentage of the participant’s annual base salary, and is used as a guide by which to measure the appropriate and competitive value of the
annual equity grant to be proposed by the Company for approval by the Compensation committee. In your position of Executive Vice President of Corporate Affairs, your target annual long-term incentive value is two hundred percent (200%) of your
annual base salary. 
 As an incentive to enter into the employ of the Company, you will be eligible to receive a special bonus payment in the amount of
$150,000 (gross before deductions) payable ninety (90) days following your date of employment with the Company. You must be an active employee with the Company on the date of payment in order to remain eligible for the above referenced special
bonus. 

  
 Innovations In
Regenerative Biomaterials 
 MiMedx Group, Inc. | 1775 West Oak Commons Ct NE | Marietta, GA 30062 | 770.651.9100 | Fax 770.590.3550
| www.mimedx.com 

 The Company will make a recommendation to the MiMedx Board of Directors that the Company enters into a
Change in Control Severance and Restrictive Covenant Agreement (the “Severance Agreement”) between you and MiMedx. The Severance Agreement will be proposed at the April 25, 2018 Board of Directors meeting. The following is a summary
of certain of the terms and conditions of the proposed Severance Agreement: If you are an employee of the Company at the time of a Change in Control (as defined in the Severance Agreement), you shall be entitled to the compensation and benefits as
described below upon the subsequent termination of your employment with the Company by you or by the Company during the term of the Severance Agreement, unless such termination is as a result of (i) your death; (ii) your disability;
(iii) your retirement; (iv) your termination by the Company for Cause (as defined in the Severance Agreement); or (v) your decision to terminate your employment other than for Good Reason (as defined in the Severance Agreement). 

After a Change in Control (as defined in the Severance Agreement) of the Company has been consummated, if the Company terminates your employment other than
pursuant to the disqualified reasons referenced above or if you terminate your employment for Good Reason (as defined in the Severance Agreement), then the Company shall pay or provide to you, as severance compensation and in consideration of your
adherence to all post termination terms and conditions defined in the Severance Agreement, the following: 
 (a) An amount equal to one and
three quarters (1.75) times your annual base compensation and targeted base bonus on the date of the Change in Control (as defined in the Severance Agreement) which amount shall be paid to you in cash on or before the fifth business day
following the date of termination of employment; and 
 (b) For a period of twenty-one
(21) months following your date of termination of employment, the following benefits are provided to you: 
  

	 	i.	 if you elect and remain eligible for COBRA coverage for you and anyone entitled to claim under or through you,
you shall be entitled to purchase the COBRA coverage under the group medical plan or dental plan at a subsidized COBRA rate equal to the “active” employee contribution rate for you and your dependents (where applicable); and

  

	 	ii.	 your participation in the life or other similar insurance or death benefit plan, or other present or future
similar group employee benefit plan or program of the Company (excluding short-term or long-term disability insurance) for which key Employees are eligible at the date of a Change in Control, to the same extent as if you had continued to be an
employee of the Company during such period and such benefits shall, to the extent not fully paid under any such plan or program, be paid by the Company. 

The Company’s obligation to provide the above severance payments is expressly contingent upon the Company’s prior receipt of an executed copy of the
Company’s General Release (the “General Release”). The Company will have no obligation to provide severance payments in the event that you (i) do not deliver to the Company an executed General Release, or (ii) do deliver an
executed General Release to the Company, but you breach any representation, warranty or covenant of the General Release after delivery. 

  
 Innovations In
Regenerative Biomaterials 
 MiMedx Group, Inc. | 1775 West Oak Commons Ct NE | Marietta, GA 30062 | 770.651.9100 | Fax 770.590.3550
| www.mimedx.com 

 For purposes of the Severance Agreement, “Change in Control” shall mean and be deemed to have
occurred on the earliest to occur of a change in the ownership of the Company, a change in the effective control of the Company, a change in ownership of a substantial portion of the Company’s assets or a disposition of a substantial portion of
the Company’s assets, all as defined below: 
 (a) A change in the ownership of the Company occurs on the date that any one person, or
more than one person acting as a group, acquires ownership of stock of the Company which, together with stock held by such person or group, represents more than fifty percent (50%) of the total fair market value or total voting power of the stock of
the Company. An increase in the percentage of stock owned by any one person, or persons acting as a group, as a result of a transaction in which the Company acquires its stock in exchange for property will be treated as an acquisition of stock. 

(b) A change in the effective control of the Company occurs on the date that either: any one person, or more than one person acting as a group
becomes the beneficial owner of stock of the Company possessing more than fifty percent (50%) of the total voting power of the stock of the Company; or a majority of members of the Company’s board of directors is replaced during any 24-month period by directors whose appointment or election is not endorsed by at least two-thirds (2/3) of the members of the Company’s board of directors who were
directors prior to the date of the appointment or election of the first of such new directors. 
 (c) A change in the ownership of a
substantial portion of the Company’s assets occurs on the date that any one person, or more than one person acting as a group, acquires (or has acquired during the 12-month period ending on the date of
the most recent acquisition by such person or persons) assets from the Company that have a total fair market value equal to seventy-five percent (75%) or more of the total fair market value of all of the assets of the Company immediately prior to
such acquisition or acquisitions. The transfer of assets by the Company is not treated as a change in the ownership of such assets if the assets are transferred to an entity more than fifty percent (50%) of the total value or voting power of which
is owned, directly or indirectly, by the Company. 
 (d) A disposition of a substantial portion of the Company’s assets occurs on the
date that the Company transfers assets by sale, lease, exchange, distribution to shareholders, assignment to creditors, foreclosure or otherwise, in a transaction or transactions not in the ordinary course of the Company’s business (or has made
such transfers during the 12-month period ending on the date of the most recent transfer of assets) that have a total fair market value equal to seventy-five percent (75%) or more of the total fair market
value of all of the assets of the Company as of the date immediately prior to the first such transfer or transfers. The transfer of assets by the Company is not treated as a disposition of a substantial portion of the Company’s assets if the
assets are transferred to an entity, more than fifty percent (50%) of the total value or voting power of which is owned, directly or indirectly, by the Company. 

  
 Innovations In
Regenerative Biomaterials 
 MiMedx Group, Inc. | 1775 West Oak Commons Ct NE | Marietta, GA 30062 | 770.651.9100 | Fax 770.590.3550
| www.mimedx.com 

 In the event of the involuntary termination of your employment by the Company prior to a Change in Control
for reasons other than for “Cause”, or your voluntary termination of your employment prior to a Change in Control with “Good Reason,” you will be eligible to receive severance payments for a period of twelve (12) months
following the termination date (the “Non-CIC Severance Period”) equivalent to your annualized base salary and your annualized target base bonus (the
“Non-CIC Severance Agreement”). Although such payments will be measured by your salary at the time of termination of employment, you will no longer be an employee of the Company after your
termination date. Such payments will be made ratably over the Non-CIC Severance Period according to the Company’s standard payroll schedule and shall be subject to applicable withholdings, provided,
however, that no such payments will be made until you deliver an executed General Release, and let the applicable revocation period expire without having revoked same, as described below. Any payments to be made during such time shall be accumulated
and paid as soon as administratively practicable after the condition in the previous sentence has been satisfied. Payments made during the Non-CIC Severance Period will be limited to your base salary, less
withholdings; however, because you will no longer be an employee of the Company, you will not accrue any bonus, PTO or other compensation during the Non-CIC Severance Period. 

If the involuntary termination of your employment by the Company prior to a Change in Control for reasons other than for “Cause” or your voluntary
termination of your employment prior to a Change in Control with “Good Reason” occurs prior to the first one-third vesting tranche (33,333 shares) of the above referenced Restricted Stock Award of
100,000 shares of MiMedx Common Stock to be recommended by the Company to the Compensation Committee, the severance applicable to the Non-CIC Severance Agreement will also include an additional lump sum
payment in the amount of $750,000 (gross before deductions). Upon the vesting of the first one-third tranche (33,333 shares) of the above referenced Restricted Stock Award of 100,000 shares of MiMedx Common
Stock to be recommended by the Company to the Compensation Committee, the severance applicable to the Non-CIC Severance Agreement will no longer include the additional lump sum payment in the amount of
$750,000 (gross before deductions). 
 For the duration of the Non-CIC Severance Period, you and anyone entitled to
claim under or through you shall also be entitled to all benefits under any group medical plan, dental plan, vision plan or other present or future similar group employee benefit plan or program of the Company for which employees are eligible as of
the date of termination. To receive these benefits, you must elect COBRA; however, you will continue participation in these plans at the “active” employee contribution rate for you and eligible dependents (where applicable) for the
duration of the Non-CIC Severance Period. After the Non-CIC Severance Period, you will be able to continue under COBRA to the extent you remain eligible provided you pay
the full COBRA rate. Other benefits not described above will be continued under the Company’s then existing benefit plans and policies in accordance with, and to the extent generally permitted with respect to any terminating employees under
such plans and policies in effect on the date of termination. 

  
 Innovations In
Regenerative Biomaterials 
 MiMedx Group, Inc. | 1775 West Oak Commons Ct NE | Marietta, GA 30062 | 770.651.9100 | Fax 770.590.3550
| www.mimedx.com 

 The Company’s obligation to provide the above severance payments is expressly contingent upon the
Company’s prior receipt of an executed copy of the Company’s General Release (the “General Release”). The Company will have no obligation to provide severance payments in the event that you (i) do not deliver to the Company
an executed General Release and let any applicable revocation period expire without having revoked same, within thirty (30) days after the termination date, or (ii) do deliver an executed General Release to the Company, but you breach any
representation, warranty or covenant of the General Release after delivery. 
 For purposes of this Non-CIC
Severance Agreement, “Cause” shall mean (i) your willful failure, neglect or refusal, as determined by the reasonable judgment of the Company, to perform the material duties of your position, which willful failure, neglect or refusal
has not been cured by you within thirty (30) days of receipt of detailed written notice from the Company specifying the acts or omissions constituting such failure, neglect or refusal and you have not at any time thereafter repeated such
failure or failed to sustain such cure; (ii) any misconduct by you that has the effect of injuring the reputation or business of the Company or any of its affiliates in any material respect; (iii) your continued or repeated absence from
the Company, unless such absence is (a) approved or excused by the CEO of MiMedx or (b) is the result of your illness, disability or incapacity (in which event (viii) below shall control); (iv) your use of illegal drugs while on
or off duty or drunkenness while on duty; (v) your conviction for the commission of a felony; (vi) the commission by you of an act of fraud, deceit, intentional material misrepresentation or embezzlement against the Company or any of its
affiliates; (vii) knowing, intentional or willful withholding of information from the Company regarding or related to the criminal activity of any supplier, distributor, or vendor of the Company; or (viii) your disability, which shall mean
your inability to perform the essential functions of your position, with or without reasonable accommodation by the Company, for an aggregate of one hundred twenty (120) days (whether or not consecutive) during any twelve (12)-month period
during your employment with the Company. 
 For purposes of this “Cause” provision, no act or failure to act on your part shall be considered
“willful” unless it is done, or omitted to be done, by you in bad faith or without reasonable belief that your action or omission was in the best interests of the Company. Any act, or failure to act, based upon authority given by the
Company’s CEO, COO or their designated representative(s) or upon the advice of counsel for the Company shall be conclusively presumed to be done, or omitted to be done, by you in good faith and in the best interests of the Company. 

For purposes of this Non-CIC Severance Agreement, “Good Reason” shall mean the occurrence of any of the
following events, without your express written consent: (i) material diminution in your Base Salary; (ii) material diminution in your duties, authorities or responsibilities (other than temporarily while physically or mentally
incapacitated or as required by applicable law); (iii) any material breach of the provisions of this letter by the Company; (iv) relocation of your primary work location by more than fifty (50) miles from its then current location
without your consent; or (v) change in your direct reporting relationship to someone other than the CEO unless offered the position of CEO. 

  
 Innovations In
Regenerative Biomaterials 
 MiMedx Group, Inc. | 1775 West Oak Commons Ct NE | Marietta, GA 30062 | 770.651.9100 | Fax 770.590.3550
| www.mimedx.com 

 If you believe that Good Reason exists, you shall provide the Company with written notice detailing the
specific circumstances alleged to constitute Good Reason within thirty (30) days of the initial existence of such circumstances, and the Company shall have a period of thirty (30) days following receipt of such notice to cure such event
(if susceptible to cure). If you do not resign for Good Reason within thirty (30) days after the expiration of the applicable cure period (provided the Company did not cure same), then you will be deemed to have irrevocably waived your right to
terminate for Good Reason with respect to such grounds. 
 Initially and throughout your first year of employment, the Company will not require your
relocation to the Marietta, Georgia area, but rather allow you to commute on a weekly basis from your residence in Chatham, New Jersey to Marietta, Georgia. You will be expected to primarily work from the Company’s Marietta, Georgia office and
maintain a schedule averaging no less than four and one-half (4.5) days per week working from the Marietta office or traveling on Company business, unless otherwise agreed between you and the CEO of
MiMedx. During this time, you will be permitted to maintain your primary residency in Chatham, New Jersey. At Company expense, MiMedx will secure an apartment for you in the Marietta, Georgia area for you to reside during the days of the week that
you work from the Company’s Marietta Office. The Company will pay for your weekly airfare to and from New Jersey and Atlanta. If you choose to remain in the Atlanta area over a weekend, the Company will pay for your spouse’s airfare to and
from New Jersey and Atlanta for one weekend each month. Also at Company expense, MiMedx will secure a rental car on a long-term rental arrangement that you will be able to use during your time in Marietta, and not have to do a car return and pick up
every time you fly to and from New Jersey to Atlanta. 
 Following one year of employment with the Company, MiMedx does expect that you will relocate to the
Marietta, Georgia area. If you would be interested in relocation from your primary residence in Chatham, New Jersey to the Marietta, Georgia area sooner than one year after you commence employment, the Company will accommodate that desire. Before
the start of your relocation process, the Company will provide you with an appropriate relocation package to include relocation benefits and reimbursement of incurred expenses associated with: 1) the movement of household goods and vehicles,
including appliance servicing, storage, automobile transport, personal towing (if desired) of your personal belongings, and movement of the contents of your wine cellar; 2) house hunting trips to the Atlanta area; 3) temporary living expenses prior
to moving into your new residence in the Atlanta area; 4) sale of your residence in Chatham, New Jersey to include real estate broker fees and other expenses customarily required to be paid by the seller; 5) purchase of your new residence to include
legal fees and other transactional expenses required to be paid by the buyer; and 6) reimbursement of the first tier tax consequences of the amounts of the above-reimbursed relocation expenses which are taxable to you. For each of the above areas of
relocation benefits, the Company will establish a relocation budget and expenditure ceiling. 
 Should you voluntarily elect to leave the employ of the
Company within twelve (12) months following the completion of all of the above relocation expenses, you will be required to repay to the Company the full amount of the reimbursed relocation expenses. 

  
 Innovations In
Regenerative Biomaterials 
 MiMedx Group, Inc. | 1775 West Oak Commons Ct NE | Marietta, GA 30062 | 770.651.9100 | Fax 770.590.3550
| www.mimedx.com 

 You will be permitted to continue serving on the Boards of Directors in which you currently serve provided
1) the nature of the business of those organizations does not create a conflict of interest with your position with MiMedx and the business of MiMedx; and 2) the time required for such Board participation and activities is reasonable. Any requests
for future membership on other Boards will follow the Company’s standard disclosure requirements and review for conflict of interest and other factors that may be detrimental or disadvantageous to the Company. 

You will be eligible to participate in the Company’s medical, dental, vision, life insurance, and disability benefits programs the first day of the month
following your first day of employment. You will be eligible to participate in the MiMedx Group 401(k) Plan effective the first day of the month following your first day of employment. 

Each such benefit shall be provided in accordance with the terms of the applicable benefit plans, which may be revised at any time at the Company’s
discretion. A summary of the Company’s benefits is enclosed for your review. More detailed benefits eligibility and enrollment information will be sent to you shortly after you begin employment. 

This offer is contingent upon a favorable background investigation and pre-employment drug screen result. Once we
receive your consent for background screening, you will receive an email from Pembrooke with instructions for the drug screen process and a Chain of Custody (COC) Registration number for specimen collection. Drug screenings must be completed
within 48 hours of the Company’s receipt of your executed consent for background screening. 
 The email from Pembrooke will also contain the addresses
and phone numbers of the lab facilities closest to your home address. To find another lab facility that may be more convenient for you, please call 1-800939-4782, Monday — Friday from 6am to midnight
(CST). No appointments are necessary. Please make sure that you bring the COC Registration number and photo identification, such as your driver’s license. 

This offer is also contingent on the receipt of favorable references from selected former employers. 

The Company is committed to the highest standards of integrity and to treating its customers, employees, fellow workers, business partners and competitors in
good faith and fair dealing. We expect employees to share the same standard and values. By accepting this offer, you agree that throughout your employment, you will observe all of the Company’s rules governing conduct of its business and
employees, including its policies protecting employees from illegal discrimination and harassment, as those rules and policies may be amended from time to time. 

As an employee of MiMedx, you are prohibited from the use or disclosure of confidential information or trade secrets obtained from your past employers. If you
have any such documents in your possession, you are expected to return them to the respective organization, and during the course of your employment with the Company, not bring onto MiMedx premises or utilize in any manner such documents,
confidential information or trade secrets. While you have not made the Company aware of any such information in your possession, we urge you to abide by this prohibition if such information is currently in your possession. 

  
 Innovations In
Regenerative Biomaterials 
 MiMedx Group, Inc. | 1775 West Oak Commons Ct NE | Marietta, GA 30062 | 770.651.9100 | Fax 770.590.3550
| www.mimedx.com 

 This offer of employment is contingent on the absence of any restrictive covenants that would prevent you
from conducting the duties and responsibilities of your position with MiMedx. By your acceptance of this offer, you represent that you are not a party to any non-disclosure, restrictive covenant or invention
assignment agreements. If you become aware of any such agreements to which you are a party, by your acceptance of this offer, you agree to provide us with a copy of such additional agreements. 

As a condition of your employment, you will be required to sign and comply with the enclosed MiMedx Confidentiality and
Non-Solicitation Agreement, MiMedx Employee Inventions Assignment Agreement, and MiMedx Non-Competition Agreement. If the provisions of this offer are agreeable to you,
please sign this letter to indicate your acceptance and return one copy along with the above-referenced agreements in the enclosed self-addressed envelope. 

Ed, I am delighted to extend this offer to you and look forward to an exciting and mutually rewarding business association. We look forward to you joining
MiMedx. Please feel free to contact me via email or telephonically if you have any questions. I can be reached at 770-330-4062 or tkuntz@mimedx.com. 

 

	
	Sincerely,
	
	/s/ Thornton A. Kuntz, Jr.
	Thornton A. Kuntz, Jr.
	Senior Vice President, Administration

  

	cc:	 Pete Petit 

  
 Innovations In
Regenerative Biomaterials 
 MiMedx Group, Inc. | 1775 West Oak Commons Ct NE | Marietta, GA 30062 | 770.651.9100 | Fax 770.590.3550
| www.mimedx.com 

 ACCEPTANCE 

I have read and understand the foregoing which constitutes the entire and exclusive agreement between the Company and the undersigned and supersedes all
prior or contemporaneous proposals, promises, understandings, representations, conditions, oral or written, relating to the subject matter of this agreement. I understand and agree that my employment is
at-will and is subject to the terms and conditions contained herein. 
  

			
	 /s/ Edward J. Borkowski
	  	
April 4, 2018

	 Edward J. Borkowski
	  	Date

  
 Innovations In
Regenerative Biomaterials 
 MiMedx Group, Inc. | 1775 West Oak Commons Ct NE | Marietta, GA 30062 | 770.651.9100 | Fax 770.590.3550
| www.mimedx.comEX-10.24

 Exhibit 10.24 

FORM OF 
 CHANGE IN
CONTROL 
 SEVERANCE COMPENSATION 

AND 
 RESTRICTIVE COVENANT
AGREEMENT 
 THIS SEVERANCE COMPENSATION AND RESTRICTIVE COVENANT AGREEMENT (the “Agreement”) is dated as of _____
between MiMedx Group, Inc., a Florida corporation (the “Company”), and __________ (the “Executive”). 

WHEREAS, the Company has determined that it is appropriate to reinforce and encourage the continued attention and dedication of members
of the Company’s management, including the Executive, to their assigned duties without distraction in potentially disruptive circumstances arising from the possibility of a Change in Control (as hereinafter defined) of the Company; and 

WHEREAS, the severance benefits payable by the Company to the Executive as provided herein are in part intended to ensure that the
Executive receives reasonable compensation given the specific circumstances of Executive’s employment history with the Company; 

NOW, THEREFORE, in consideration of their respective obligations to one another set forth in this Agreement, and other good and
valuable consideration, the receipt, sufficiency and adequacy of which the parties hereby acknowledge, the parties to this Agreement, intending to be legally bound, hereby agree as follows: 

1. Term. This Agreement shall terminate, except to the extent that any obligation of the Company hereunder remains unpaid as of such
time, upon the earliest of (i) the Date of Termination (as hereinafter defined) of the Executive’s employment with the Company as a result of the Executive’s death, Disability (as defined in Section 3(b)) or Retirement (as
defined in Section 3(c)), by the Company for Cause (as defined in Section 3(d)) or by the Executive other than for Good Reason (as defined in Section 3(e)); and (ii) three years after the date of a Change in Control if the
Executive’s employment with the Company has not terminated as of such time. 
 2. Change in Control. For purposes of this
Agreement, “Change in Control” shall mean and be deemed to have occurred on the earliest to occur of a change in the ownership of the Company, a change in the effective control of the Company, a change in ownership of a substantial portion
of the Company’s assets or a disposition of a substantial portion of the Company’s assets, all as defined below: 
 (a) A change
in the ownership of the Company occurs on the date that any one person, or more than one person acting as a group, acquires ownership of stock of the Company which, together with stock held by such person or group, represents more than fifty percent
(50%) of the total fair market value or total voting power of the stock of the Company. An increase in the percentage of stock owned by any one person, or persons acting as a group, as a result of a transaction in which the Company acquires its
stock in exchange for property will be treated as an acquisition of stock. 
 (b) A change in the effective control of the Company occurs on
the date that either: any one person, or more than one person acting as a group becomes the beneficial owner of stock of the Company possessing more than fifty percent (50%) of the total voting power of the stock of the Company; or a majority of
members of the Company’s board of directors is replaced during any 24-month period by directors whose appointment or election is not endorsed by at least two-thirds
(2/3) of the members of the Company’s board of directors who were directors prior to the date of the appointment or election of the first of such new directors. 

(c) A change in the ownership of a substantial portion of the Company’s assets occurs on the date that any one person, or more than one
person acting as a group, acquires (or has acquired during the 12-month period ending on the date of the most recent acquisition by such person or persons) assets from the Company that have a total fair market
value equal to seventy-five percent (75%) or more of the total fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions. The transfer of assets by the Company is not treated as a change in the
ownership of such assets if the assets are transferred to an entity more than fifty percent (50%) of the total value or voting power of which is owned, directly or indirectly, by the Company. 

  
 1 

 (d) A disposition of a substantial portion of the Company’s assets occurs on the date
that the Company transfers assets by sale, lease, exchange, distribution to shareholders, assignment to creditors, foreclosure or otherwise, in a transaction or transactions not in the ordinary course of the Company’s business (or has made such
transfers during the 12-month period ending on the date of the most recent transfer of assets) that have a total fair market value equal to seventy-five percent (75%) or more of the total fair market value of
all of the assets of the Company as of the date immediately prior to the first such transfer or transfers. The transfer of assets by the Company is not treated as a disposition of a substantial portion of the Company’s assets if the assets are
transferred to an entity, more than fifty percent (50%) of the total value or voting power of which is owned, directly or indirectly, by the Company. 

3. Termination Following Change in Control. 

(a) General. If the Executive is still an employee of the Company at the time of a Change in Control, the Executive shall be entitled
to the compensation and benefits provided in Section 4 upon the subsequent termination of the Executive’s employment with the Company by the Executive or by the Company during the term of this Agreement, unless such termination is as a
result of (i) the Executive’s death; (ii) the Executive’s Disability; (iii) the Executive’s Retirement; (iv) the Executive’s termination by the Company for Cause; or (v) the Executive’s decision to
terminate employment other than for Good Reason. 
 (b) Disability. The term “Disability” as used in this Agreement shall
mean termination of the Executive’s employment by the Company as a result of the Executive’s incapacity due to physical or mental illness, provided that the Executive shall have been absent from Executive’s duties with the Company on
a full-time basis for six consecutive months and such absence shall have continued unabated for 30 days after Notice of Termination as described in Section 3(f) is thereafter given to the Executive by the Company. 

(c) Retirement. The term “Retirement” as used in this Agreement shall mean termination of the Executive’s employment by
the Company based on the Executive’s having attained age 65 or such later retirement age as shall have been established pursuant to a written agreement between the Company and the Executive. 

(d) Cause. The term “Cause” for purposes of this Agreement shall mean the Company’s termination of the Executive’s
employment on the basis of criminal or civil fraud on the part of the Executive involving a material amount of funds of the Company. Notwithstanding the foregoing, the Executive shall not be deemed to have been terminated for Cause unless and until
there shall have been delivered to the Executive a copy of a resolution duly adopted by the affirmative vote of not less than three-quarters of the entire membership of the Company’s Board of Directors at a meeting of the Board called and held
for such purpose (after reasonable notice to the Executive and an opportunity for the Executive, together with the Executive’s counsel, to be heard before the Board) finding that in the good faith opinion of the Board the Executive was guilty
of conduct set forth in the first sentence of this Section 3(d) and specifying the particulars thereof in detail. For purposes of this Agreement only, the preparation and filing of fictitious, false or misleading claims in connection with any
federal, state or other third party medical reimbursement program, or any other violation of any rule or regulation in respect of any federal, state or other third party medical reimbursement program by the Company or any subsidiary of the Company
shall not be deemed to constitute “criminal fraud” or “civil fraud.” 
 (e) Good Reason. For purposes of this
Agreement, “Good Reason” shall mean any of the following actions taken by the Company without the Executive’s express written consent: 

(i) The assignment to the Executive by the Company of duties inconsistent with, or a material adverse alteration of the powers and functions
associated with, the Executive’s position, duties, responsibilities and status with the Company prior to a Change in Control, or an adverse change in the Executive’s titles or offices as in effect prior to a Change in Control, or any
removal of the Executive from or any failure to re-elect the Executive to any of such positions, except in connection with the termination of Executive’s employment for Disability, Retirement or Cause or
as a result of the Executive’s death or by the Executive other than for Good Reason; 
 (ii) A reduction in the Executive’s base
salary as in effect on the date hereof or as the same may be increased from time to time during the term of this Agreement; 

  
 2 

 (iii) Any failure by the Company to continue in effect any benefit plan, program or
arrangement (including, without limitation, any profit sharing plan, group annuity contract, group life insurance supplement, or medical, dental, accident and disability plans) in which the Executive was eligible to participate at the time of a
Change in Control (hereinafter referred to as “Benefit Plans”), or the taking of any action by the Company which would adversely affect the Executive’s participation in or materially reduce the Executive’s benefits under any such
Benefit Plan, unless a comparable substitute Benefit Plan shall be made available to the Executive, or deprive the Executive of any fringe benefit enjoyed by the Executive at the time of a Change in Control; 

(iv) Any failure by the Company to continue in effect any incentive plan or arrangement (including, without limitation, any bonus or
contingent bonus arrangements and credits and the right to receive performance awards and similar incentive compensation benefits) in which the Executive is participating at the time of a Change in Control (or any other plans or arrangements
providing Executive with substantially similar benefits) (hereinafter referred to as “Incentive Plans”) or the taking of any action by the Company which would adversely affect the Executive’s participation in any such Incentive Plan
or reduce the Executive’s benefits under any such Incentive Plan, expressed as a percentage of Executive’s base salary, by more than five percentage points in any fiscal year as compared to the immediately preceding fiscal year, or any
action to reduce Executive’s bonuses under any Incentive Plan by more than five percentage points (5%) in any fiscal year as compared to the immediately preceding fiscal year; 

(v) Any failure by the Company to continue in effect any plan or arrangement to receive securities of the Company (including, without
limitation, the Company’s Assumed 2006 Stock Incentive Plan and the Company’s 2016 Equity and Cash Incentive Plan, any other plan or arrangement to receive and exercise stock options, stock appreciation rights, restricted stock or grants
thereof) in which the Executive is participating or has the right to participate in prior to a Change in Control (or plans or arrangements providing Executive with substantially similar benefits) (hereinafter referred to as “Securities
Plans”) or the taking of any action by the Company which would adversely affect the Executive’s participation in or materially reduce the Executive’s benefits under any such Securities Plan, unless a comparable substitute Securities
Plan shall be made available to the Executive; 
 (vi) A relocation of the Company’s principal executive offices to a location more
than fifty (50) miles from its location immediately prior to a Change in Control, or the Executive’s relocation to any place other than the Company’s principal executive offices, except for required travel by the Executive on the
Company’s business to an extent substantially consistent with the Executive’s business travel obligations immediately prior to a Change in Control; 

(vii) Required work and or travel schedule that is not substantially consistent with the Executive’s work and/or business travel
schedule immediately prior to a Change in Control: 
 (viii) Any failure by the Company to provide the Executive with the number of Paid
Time Off (“PTO”) days (or compensation therefor at termination of employment) accrued to the Executive through the Date of Termination; 

(ix) Any material breach by the Company of any provision of this Agreement; 

(viii) Any failure by the Company to obtain the assumption of this Agreement by any successor or assign of the Company effected in accordance
with the provisions of Section 7(a) hereof; 
 (ixi) Any purported termination of the Executive’s employment that is not effected
pursuant to a Notice of Termination satisfying the requirements of Section 3(f), and for purposes of this Agreement, no such purported termination shall be effective; or 

(xi) Any proposal or request by the Company after the Effective Date to require that the Executive enter into a non-competition agreement with the Company where the terms of such agreement as to its scope or duration are greater than the terms set forth in Section 5 hereof. 

(f) Notice of Termination. Any termination of the Executive’s employment by the Company for a reason specified in
Section 3(b), 3(c) or 3(d) shall be communicated to the Executive by a Notice of Termination prior to the effective date of the termination. For purposes of this Agreement, a “Notice of Termination” shall mean a written notice which
shall indicate whether such termination is for the reason set forth in Section 3(b), 3(c) or 3(d) and which sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Executive’s
employment under the provision so indicated. For purposes of this Agreement, no termination of the Executive’s employment by the Company shall constitute a termination for Disability, Retirement or Cause unless such termination is preceded by a
Notice of Termination. 

  
 3 

 (g) Date of Termination. “Date of Termination” shall mean (a) if the
Executive’s employment is terminated by the Company for Disability, 30 days after a Notice of Termination is given to the Executive (provided that the Executive shall not have returned to the performance of the Executive’s duties on a
full-time basis during such 30-day period) or (b) if the Executive’s employment is terminated by the Company or the Executive for any other reason, the date on which the Executive’s termination
is effective; provided that, if within 30 days after any Notice of Termination is given to the Executive by the Company the Executive notifies the Company that a dispute exists concerning the termination, the Date of Termination shall be the date
the dispute is finally determined whether by mutual agreement by the parties or upon final judgment, order or decree of a court of competent jurisdiction (the time for appeal therefrom having expired and no appeal having been perfected). For
purposes of this Agreement, the Executive’s employment by the Company shall be deemed terminated upon the date the Executive incurs a “separation from service” within the meaning of Section 409A(a)(2)(A)(i) of the Internal
Revenue Code of 1986, as amended (“Code”), and the regulations issued thereunder. 
 4. Compensation and Benefits upon
Termination of Employment. 
 (a) If the Company shall terminate the Executive’s employment after a Change in Control other than
pursuant to Section 3(b), 3(c) or 3(d) and Section 3(f), or if the Executive shall terminate Executive’s employment for Good Reason, in either case, on or within three years after a Change in Control, then the Company shall pay to the
Executive, as severance compensation and in consideration of the Executive’s adherence to the terms of Section 5 hereof, subject to Section 17 below, the following: 

(i) On the Date of Termination, the Company shall become liable to the Executive for an amount equal to _________ (_____) times the
Executive’s annual base compensation and targeted base bonus on the date of the Change in Control, which amount shall be paid to the Executive in cash on or before the fifth business day following the Date of Termination. 

(ii) For a period of _____ (___) months following the Date of Termination, the following benefits are provided to the Executive: a) if the
Executive elects and remains eligible for COBRA coverage for the Executive and anyone entitled to claim under or through the Executive, the Executive shall be entitled to purchase the COBRA coverage under the group medical plan, dental plan or
vision plan at a subsidized COBRA rate each month equal to the “active” employee contribution rate for Executive and dependents (where applicable); and b) Executive’s participation in the life or other similar insurance or death
benefit plan, or other present or future similar group employee benefit plan or program of the Company (excluding short-term or long-term disability insurance) for which key executives are eligible at the date of a Change in Control, to the same
extent as if the Executive had continued to be an employee of the Company during such period and such benefits shall, to the extent not fully paid under any such plan or program, be paid by the Company no less frequently than monthly. If Executive
is not permitted to participate in any such plan after the Date of Termination or Executive’s participation in such plans would have adverse consequences for the Company, the Company may procure comparable coverage for the Executive elsewhere
on the same relative terms. 
 (iii) Notwithstanding any other provision of this Agreement, it is intended that any payment or benefit
provided pursuant to or in connection with this Agreement that is considered to be nonqualified deferred compensation subject to Section 409A of the Code shall be provided and paid in a manner, and at such time and in such form, as complies
with the applicable requirements of Section 409A of the Code. If and to the extent required by Section 409A of the Code, no payment or benefit shall be made or provided to a “specified employee” (as defined below) prior to the
six (6) month anniversary of the Executive’s separation from service (within the meaning of Section 409A(a)(2)(A)(i) of the Code) or, if earlier, Executive’s death. The amounts provided for in this Agreement that constitute
nonqualified deferred compensation shall be paid as soon as (and no later than thirty (30) days after) the six month deferral period ends or, if earlier, no later than thirty (30) days after the Executive’s death. In the event that
benefits are required to be deferred, any such benefit may be provided during such deferral period at the Executive’s expense, with the Executive having a right to reimbursement from the Company for the amount of any premiums or expenses paid
by the Executive once the deferral period ends (as described above). For this purpose, a specified employee shall mean an individual who is a key employee (as defined in Section 416(i) of the Code without regard to Section 416(i)(5) of the
Code) of the Company at any time during the 12-month period ending on each 

  
 4 

 
December 31 (the “identification date”). If the Executive is a key employee as of an identification date, the Executive shall be treated as a specified employee for the 12-month period beginning on the April 1 following the identification date. Notwithstanding the foregoing, the Executive shall not be treated as a specified employee unless any stock of the Company or a Company
or business affiliated with it pursuant to Sections 414(b) or (c) of the Code is publicly traded on an established securities market or otherwise. 

(b) The parties hereto agree that the payments provided in Section 4(a) hereof are reasonable compensation in light of the
Executive’s services rendered to the Company and in consideration of the Executive’s adherence to the terms of Section 5 hereof. Neither party shall contest the payment of such benefits as constituting an “excess parachute
payment” within the meaning of Section 280G(b)(1) of the Code. In the event that the Executive becomes entitled to the compensation and benefits described in Section 4(a) hereof (the “Compensation Payments”) as a result of
such Compensation Payments and any other benefits or payments required to be taken into account under Code Section 280G(b)(2) (“Parachute Payments”), any of such Parachute Payments must be reported by the Company as “excess
parachute payments” and are therefore not deductible by the Company, the Company shall not have any obligation and shall not pay to the Executive any additional amount or gross-up payment related to any
of the tax imposed on the Executive by Section 4999 of the Code. The tax, if any, imposed on the Executive by Section 4999 of the Code shall be the full responsibility of the Executive (subject to withholding by the Company). 

(c) The payments provided in Section 4(a) above shall be in lieu of any other severance compensation otherwise payable to Executive under
any other agreement between Executive and the Company or the Company’s established severance compensation policies; provided, however, that nothing in this Agreement shall affect or impair Executive’s vested rights under any other employee
benefit plan or policy of the Company. For the avoidance of doubt, if more than one Change in Control occurs during the term hereof, the term of this Agreement shall not expire until three years after the date of the latest such Change in Control to
occur and the amount of compensation payable under Section 4(a)(1) shall be based upon the highest annual base salary, targeted base bonus and car allowance payable to Executive on the date of any such Change in Control (to the extent not paid
previously in connection with an earlier Change in Control), but Executive shall not be entitled to receive severance compensation under Section 4(a) more than once. 

5. Protective Covenants. 

(a) Definitions. 
 This
Subsection sets forth the definition of certain capitalized terms used in Subsections (a) through (f) of this Section 5. 
 (i)
“Competing Business” shall mean a business (other than the Company) that, directly or through a controlled subsidiary or through an affiliate, is an integrated developer, processor, and/or marketer of a) collagen based biomaterials
and products, b) bioimplants processed from human amniotic membrane, c) other amnion based products, d) tissue regeneration products, e) human allograft including skin and bone products, and f) other future products developed, processed,
manufactured or marketed by the Company (collectively, “Competing Services”). Notwithstanding the foregoing, no business shall be deemed a “Competing Business” unless, within at least one of the business’s three most
recently concluded fiscal years, that business, or a division of that business, derived more than twenty percent (20%) of its gross revenues or more than $2,000,000 in gross revenues from the provision of Competing Services. 

(ii) “Competitive Position” shall mean: (A) the Executive’s direct or indirect equity ownership (excluding
ownership of less than one percent (1%) of the outstanding common stock of any publicly held Company) or control of any portion of any Competing Business; or (B) any employment, consulting, partnership, advisory, directorship, agency,
promotional or independent contractor arrangement between the Executive and any Competing Business where the Executive performs services for the Competing Business substantially similar to those the Executive performed for the Company. 

(iii) “Covenant Period” shall mean the period of time from the date of this Agreement to the date that is twelve
(12) months after the Date of Termination. 

  
 5 

 (iv) “Customers” shall mean actual customers, clients or referral sources
to or on behalf of which the Company provides Competing Services (A) during the two years prior to the date of this Agreement and (B) during the Covenant Period. 

(v) “Restricted Territory” shall mean the 48 continuous states of the continental United States. 

(b) Limitation on Competition. In consideration of the Company’s entering into this Agreement, the Executive agrees that during
the Covenant Period, the Executive will not, without the prior written consent of the Company, anywhere within the Restricted Territory, either directly or indirectly, alone or in conjunction with any other party, accept, enter into or take any
action in conjunction with or in furtherance of a Competitive Position (other than action to reject an unsolicited offer of a Competitive Position). 

(c) Limitation on Soliciting Customers. In consideration of the Company’s entering into this Agreement, the Executive agrees that
during the Covenant Period, the Executive will not, without the prior written consent of the Company, alone or in conjunction with any other party, solicit, divert or appropriate or attempt to solicit, divert or appropriate on behalf of a Competing
Business with which Executive has a Competitive Position any Customer located in the Restricted Territory (or any other Customer with which the Executive had any direct contact on behalf of the Company) for the purpose of providing the Customer or
having the Customer provided with a Competing Service. 
 (d) Limitation on Soliciting Personnel or Other Parties. In consideration
of the Company’s entering into this Agreement, the Executive hereby agrees that Executive will not, without the prior written consent of the Company, alone or in conjunction with any other party, solicit or attempt to solicit any employee,
consultant, contractor, independent broker or other personnel of the Company or any subsidiary of the Company to terminate, alter or lessen that party’s affiliation with the Company or to violate the terms of any agreement or understanding
between such employee, consultant, contractor or other person and the Company or any subsidiary of the Company. 
 (e)
Acknowledgement. The parties acknowledge and agree that the Protective Covenants are reasonable as to time, scope and territory given the Company’s need to protect its trade secrets and confidential business information and given the
substantial payments and benefits to which the Executive may be entitled pursuant to this Agreement. 
 (f) Remedies. The parties
acknowledge that any breach or threatened breach of a Protective Covenant by the Executive is reasonably likely to result in irreparable injury to the Company, and therefore, in addition to all remedies provided at law or in equity, the Executive
agrees that the Company shall be entitled to a temporary restraining order and a permanent injunction to prevent a breach or contemplated breach of the Protective Covenant. If the Company seeks an injunction, the Executive waives any requirement
that the Company post a bond or any other security. 
 6. No Obligation to Mitigate Damages; No Effect on Other Contractual Rights.

 (a) All compensation and benefits provided to the Executive under this Agreement are in consideration of the Executive’s services
rendered to the Company and of the Executive’s adhering to the terms set forth in Section 5 hereof and the Executive shall not be required to mitigate damages or the amount of any payment provided for under this Agreement by seeking other
employment or otherwise, nor shall the amount of any payment provided for under this Agreement be reduced by any compensation earned by the Executive as the result of employment by another employer after the Date of Termination, or otherwise. 

(b) The provisions of this Agreement, and any payment provided for hereunder, shall not reduce any amounts otherwise payable, or in any way
diminish the Executive’s existing rights, or rights which would accrue solely as a result of the passage of time, under any Benefit Plan, Incentive Plan or Securities Plan, employment agreement or other contract, plan or arrangement. 

7. Successor to the Company. 

(a) The Company will require any successor or assign (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or
substantially all of the business and/or assets of the Company (“Successor or 

  
 6 

 
Assign”), by agreement in form and substance satisfactory to the Executive, expressly, absolutely and unconditionally to assume and agree to perform this Agreement in the same manner and to
the same extent that the Company would be required to perform it if no such succession or assignment had taken place. Any failure of the Company to obtain such agreement prior to the effectiveness of any such succession or assignment shall be a
material breach of this Agreement and shall entitle the Executive to terminate the Executive’s employment for Good Reason. As used in this Agreement (except for purposes of defining “Change in Control” in Section 2),
“Company” shall mean the Company as hereinbefore defined and any Successor or Assign to the Company. If at any time during the term of this Agreement the Executive is employed by any Company a majority of the voting securities of which is
then owned by the Company, “Company” as used in Sections 3, 4, 12 and 14 hereof shall in addition include such employer. In such event, the Company agrees that it shall pay or shall cause such employer to pay any amounts owed to the
Executive pursuant to Section 4 hereof. 
 (b) This Agreement shall inure to the benefit of and be enforceable by the Executive’s
personal and legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If the Executive should die while any amounts are still payable to Executive hereunder, all such amounts, unless otherwise
provided herein, shall be paid in accordance with the terms of this Agreement to the Executive’s devisee, legatee, or the designee or, if there be no such designee, to the Executive’s estate. 

8. Notice. For purposes of this Agreement, notices and all other communications provided for in this Agreement shall be in writing and
shall be deemed to have been duly given when delivered by overnight courier service (e.g., Federal Express) or mailed by United States certified mail, return receipt required, postage prepaid, as follows: 

If to Company: 
 MiMedx Group,
Inc. 
 1775 West Oak Commons Court 

Marietta, GA 30062 
 Attention:
General Counsel 
 If to Executive: 

_______________________ 

_______________________ 

_______________________ 
 or such other address
as either party may have furnished to the other in writing in accordance herewith, except that notices of change of address shall be effective only upon receipt. 

9. Miscellaneous. No provisions of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge
is agreed to in writing signed by the Executive and the Company. No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by such other
party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. No agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have
been made by either party which are not set forth expressly in this Agreement. This Agreement shall be governed by and construed in accordance with the laws of the State of Florida. 

10. Validity. The invalidity or unenforceability of any provisions of this Agreement shall not affect the validity or enforceability of
any other provision of this Agreement, which shall remain in full force and effect. 
 11. Counterparts. This Agreement may be
executed in one or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument. 

12. Legal Fees and Expenses. The Company shall pay all legal fees, expenses and damages which the Executive may incur as a result of
the Executive’s instituting legal action to enforce Executive’s rights hereunder, or in the event the Company contests the validity, enforceability or the Executive’s interpretation of, or determinations under, this Agreement. If the
Executive is the prevailing party or recovers any damages in such legal action, the Executive shall be entitled to receive in addition thereto pre-judgment and post-judgment interest on the amount of such
damages. All such amounts will be paid or reimbursed no later than thirty (30) days after Executive incurs such fees, expenses and damages or is entitled to such pre-judgment or post-judgment interest.

  
 7 

 13. Section 409A Indemnification. Notwithstanding any other provision of this
Agreement, it is intended that any payment or benefit which is provided pursuant to or in connection with this Agreement which is considered to be nonqualified deferred compensation subject to Section 409A of the Code shall be provided and paid
in a manner, and at such time and in such form, as complies with the applicable requirements of Section 409A of the Code. The Company and the Executive shall cooperate to modify this Agreement as necessary to comply with the requirements of
Section 409A of the Code. In the event the Company does not so cooperate (and assuming the Company can correct such matter without the Company or Executive incurring any additional taxes, penalties or interest), it shall indemnify and hold
harmless the Executive on an after-tax basis from any tax or interest penalty imposed under Section 409A of the Code with respect to any payment or benefit provided pursuant to this Agreement or any other
plan or arrangement sponsored or maintained by the Company to the extent such tax or interest penalty is imposed solely as a result of any failure of the Company to cooperate so as to comply with Section 409A of the Code with respect to such
payment or benefit. 
 14. Severability; Modification. All provisions of this Agreement are severable from one another, and the
unenforceability or invalidity of any provision of this Agreement shall not affect the validity or enforceability of the remaining provisions of this Agreement, but such remaining provisions shall be interpreted and construed in such a manner as to
carry out fully the intention of the parties. Should any judicial body interpreting this Agreement deem any provision of this Agreement to be unreasonably broad in time, territory, scope or otherwise, it is the intent and desire of the parties that
such judicial body, to the greatest extent possible, reduce the breadth of such provision to the maximum legally allowable parameters rather than deeming such provision totally unenforceable or invalid. 

15. Confidentiality. The Executive acknowledges that Executive has previously entered into, and continues to be bound by the terms of,
the Confidentiality and Non-Solicitation Agreement, dated May 30, 2013, with the Company. 

16. Agreement Not an Employment Contract. This Agreement shall not be deemed to constitute or be deemed ancillary to an employment
contract between the Company and the Executive, and nothing herein shall be deemed to give the Executive the right to continue in the employ of the Company or to eliminate the right of the Company to discharge the Executive at any time. 

17. Limited Release. The Company’s obligation to provide severance payments and benefits to Executive under this Agreement is
expressly contingent upon the Company’s receipt no later than sixty (60) days after the Date of Termination of an executed and non-revocable Limited Release in a form customarily utilized by the
Company for such matters (the “Limited Release”). The Company will have no obligation to provide severance payments or benefits to Executive in the event that Executive (i) does not deliver to the Company an executed and non-revocable Limited Release, or (ii) does deliver an executed and non-revocable Limited Release to the Company, but Executive breaches any representation, warranty or
covenant of the Limited Release after delivery. Furthermore, the Company will be entitled to accrue and withhold any severance payment or benefits otherwise due during any period prior to submission of the Limited Release or in which the Limited
Release is revocable (in whole or in part) by Executive, provided that any such withheld payments will promptly be remitted to Executive, and severance benefits reimbursed, when the Release Agreement becomes irrevocable. To the extent such sixty
(60) day period extends over more than one calendar year, no severance payments will be payable or benefits provided until the subsequent calendar year, notwithstanding the foregoing. 

  
 8 

 IN WITNESS WHEREOF, the parties have executed this Agreement to be effective as of
the date first above written. 
  

			
	MiMedx Group, Inc.
		
	By:  	 	 
		 	Authorized Officer
	
	[      ]
	
	 
	Executive

  
 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]